Stephen Adler
Papers
1
Total Citations
147
H-Index
1
About
Stephen Adler is a leading figure in molecular imaging, with a primary focus on advancing cancer diagnostics through novel PET radiotracers. His key research areas encompass prostate cancer imaging, radiopharmaceutical development, and the integration of PET/CT with MR imaging for improved tumor characterization. Adler’s most significant contribution is his pioneering work with the synthetic amino acid radiotracer ¹⁸F-FACBC (fluciclovine), which he helped validate for detecting localized prostate cancer. His landmark 2013 study, cited over 147 times, demonstrated that ¹⁸F-FACBC PET/CT could effectively differentiate malignant prostate tissue from benign prostatic hyperplasia and normal tissue, offering a critical advantage over standard imaging. This work directly addressed a major clinical challenge—delineating intraprostatic cancers—and laid the groundwork for fluciclovine’s eventual FDA approval. By systematically comparing PET/CT findings with MR imaging and histopathologic analysis, Adler provided rigorous evidence for the tracer’s utility in guiding biopsy and treatment planning. His research has had a lasting impact on the field of oncologic imaging, helping to establish amino acid PET as a valuable tool for prostate cancer management and inspiring further investigation into targeted radiotracers for other malignancies.
Research Focus
Key Achievements
Top Papers
- 1